Last reviewed · How we verify
NCT05207618
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
NA trial testing ARBOX (QUEBRACHO AND CHESNUT EXTRACT) in Irritable Bowel Syndrome in 30 participants. Completed in 20 April 2022.
20 February 2022
Quick facts
| Lead sponsor | Hospital de Clinicas José de San Martín |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 21 September 2021 |
| Primary completion | 20 February 2022 |
| Estimated completion | 20 April 2022 |
| Sites | 1 location across Argentina |
Drugs / interventions tested
- ARBOX (QUEBRACHO AND CHESNUT EXTRACT)
Conditions studied
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
- Diarrhea — all drugs for Diarrhea →
Sponsor
Hospital de Clinicas José de San Martín
Who can join
Adults 18 to 80, any sex, with Irritable Bowel Syndrome or Diarrhea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Irritable bowel syndrome is a highly prevalent disorder and consumes many health resources. Its physiopathogenesis is multifactorial. Some of the factors involved have to do with the alteration of the intestinal microbiota, low-grade inflammation and the alteration of intestinal permeability. Specific tannins have been shown to have prebiotic effects and could be useful in treating this condition. This is an exploratory before-after study that aims to evaluate the effect of a chestnut and quebracho extract on the symptoms of IBS diarrhea predominant, serum cytokine levels, microbiota and intestinal permeability, as well as on metabolomics.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Gut Microbiome-Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders.
Sasso JM, Ammar RM, Tenchov R, Lemmel S, et al · · 2023 · cited 100× · PMID 37156006 · DOI 10.1021/acschemneuro.3c00127 -
Tannin Phytocomplex Improves IBS-D Symptoms and Gut-Brain Markers: Prospective Pilot Study.
Molino S, Piskorz MM, Lerma-Aguilera A, Mingorance FL, et al · · 2026 · PMID 42003449 · DOI 10.1002/mnfr.70451
Verify or expand the search:
- PubMed search for NCT05207618
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Irritable Bowel Syndrome
Currently open trials in the same condition.
- NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
- NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting
Other Hospital de Clinicas José de San Martín trials
Trials by the same sponsor.
- NCT06339801 — Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease · recruiting
- NCT06513611 — Cellular Immunity, Neuroendocrine, and Inflammatory Factors for Clinical Prognosis in Acute Coronary Syndrome · recruiting
- NCT06561815 — Body Composition Estimated by Bioelectrical Impedance Analysis in Patients with Acute Coronary Syndrome. · recruiting
- NCT05452603 — Usefulness of Wireless pH Monitoring in GERD Diagnosis · completed
- NCT04997720 — Impact of the Microsurgical Technique After a Theoretical-practical Course in Microsurgery · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05207618 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital de Clinicas José de San Martín
- Last refreshed: 6 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207618.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing